Frontlight ResearchEarly access
Lung cancer trials in Netherlands
130 of 141 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1Not yet taking people in NetherlandsLong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
- Where
- Amsterdam
- People
- 12 worldwide
- Run by
- USWM Ct LLC
See details and how to join2024-513033-21-00 - Phase 3TerminatedLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Arnhem, Friesland, Harderwijk, Utrecht
- Age
- 18 years and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - Phase 3Not yet taking people in NetherlandsA Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
- Where
- Amsterdam, Utrecht
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00 - Phase 2/3Not yet taking people in NetherlandsA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Leiden
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00 - Phase 3Taking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Amersfoort, Amsterdam, Groningen, Harderwijk, Leeuwarden, Nijmegen, Tilburg, Zwolle
- Age
- 18 years and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - Phase 4Taking peopleImproving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat
- Where
- Amsterdam, Geleen, Groningen, Maastricht, Rotterdam
- Age
- 18 years and over
- People
- 60
- Run by
- Maastricht University Medical Center
See details and how to joinNCT05748093 · EU 2023-505700-35-00 - Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Amersfoort, Groningen, Harderwijk, Maastricht, Nijmegen, Tilburg, Zwolle
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Groningen
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 1Active, not recruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Amsterdam, Leiden
- Age
- 18 years and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - Phase 1/2Active, not recruitingFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Amsterdam, Rotterdam
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00 - Phase 3Taking peopleImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT05522660 - Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Almelo, Ede Gld, Harderwijk, Utrecht, Zwolle
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- Groningen, Nijmegen, Rotterdam
- Age
- 18 years and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Breda, Harderwijk, Leeuwarden, Utrecht, Zwolle
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 1/2Taking peopleA Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Where
- Amsterdam, Groningen, Rotterdam
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00 - Phase 2/3Not yet taking people in NetherlandsStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Amsterdam, Harderwijk
- Age
- 18 years and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Breda, Groningen, Tilburg, Utrecht
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 2Taking peopleTarlatamab for SCLC Brain Metastases
- Where
- Amsterdam, Groningen, Maastricht, Rotterdam
- Age
- 18 years and over
- People
- 35
- Run by
- Maastricht University Medical Center
See details and how to joinNCT07402343 · EU 2025-522162-75-00 - Phase 3Taking peopleA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Where
- Almelo, Arnhem, Groningen, Leiden, Nijmegen
- Age
- 18 years and over
- People
- 310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00 - Phase 1/2Not yet taking people in NetherlandsDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00 - Phase 4Taking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Utrecht
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 3Taking peopleA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Amersfoort, Breda, Groningen, Leiden, Nieuwegein, Rotterdam, Zwolle
- Age
- 18 years and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00 - Phase 3Active, not recruitingA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Amsterdam, Arnhem, Groningen
- Age
- 18 years and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - Phase 2Taking peopleKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Where
- Deventer, Leiden
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00 - Phase 3Taking peopleDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Amsterdam, Maastricht, Rotterdam
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00